Evidence map›Paper›PMID 23785523›Full record

ArticlePloS one2013

Effect of the deletion of genes encoding proteins of the extracellular virion form of vaccinia virus on vaccine immunogenicity and protective effectiveness in the mouse model.

Clement A Meseda, Joseph Campbell, Arunima Kumar, Alonzo D Garcia, Michael Merchlinsky, Jerry P Weir

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.7field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Stability of the HSV-2Vaccines · 2020
    Article
  3. Review
  4. Article
  5. Review
  6. Article
  7. Non-coding RNAs and heme oxygenase-1 in vaccinia virus infection.Biochemical and biophysical research communications · 2014
    Article
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Clement A MesedaDivision of Viral Products, Center for Biologics Evaluation and Research, United States Food and Drug Administration, Rockville, Maryland, United States. Clement.Meseda@fda.hhs.gov
Joseph Campbell
Arunima Kumar
Alonzo D Garcia
Michael Merchlinsky
Jerry P Weir
Center for Biologics Evaluation and Research · USUnited States Food and Drug Administration · US

Funding

NIAID NIH HHS Y01 AI006153NIAID NIH HHS Y1-AI-6153-01
6 · The paper itself

Abstract

Antibodies to both infectious forms of vaccinia virus, the mature virion (MV) and the enveloped virion (EV), as well as cell-mediated immune response appear to be important for protection against smallpox. EV virus particles, although more labile and less numerous than MV, are important for dissemination and spread of virus in infected hosts and thus important in virus pathogenesis. The importance of the EV A33 and B5 proteins for vaccine induced immunity and protection in a murine intranasal challenge model was evaluated by deletion of both the A33R and B5R genes in a vaccine-derived strain of vaccinia virus. Deletion of either A33R or B5R resulted in viruses with a small plaque phenotype and reduced virus yields, as reported previously, whereas deletion of both EV protein-encoding genes resulted in a virus that formed small infection foci that were detectable and quantifiable only by immunostaining and an even more dramatic decrease in total virus yield in cell culture. Deletion of B5R, either as a single gene knockout or in the double EV gene knockout virus, resulted in a loss of EV neutralizing activity, but all EV gene knockout viruses still induced a robust neutralizing activity against the vaccinia MV form of the virus. The effect of elimination of A33 and/or B5 on the protection afforded by vaccination was evaluated by intranasal challenge with a lethal dose of either vaccinia virus WR or IHD-J, a strain of vaccinia virus that produces relatively higher amounts of EV virus. The results from multiple experiments, using a range of vaccination doses and virus challenge doses, and using mortality, morbidity, and virus dissemination as endpoints, indicate that the absence of A33 and B5 have little effect on the ability of a vaccinia vaccine virus to provide protection against a lethal intranasal challenge in a mouse model.

Indexed as

Gene DeletionAdministration, IntranasalAnimalsAntibodies, NeutralizingAntibodies, ViralCell LineDisease Models, AnimalMaleMiceRecombination, GeneticSmallpoxSmallpox VaccineVaccinationVaccinia virusViral Envelope ProteinsVirionAntibodies, NeutralizingAntibodies, ViralSmallpox VaccineViral Envelope Proteins

Identifiers

PMID23785523
PMCPMC3681963
OpenAlexW2066465020

What OpenQuestion holds

Textmetadata
LicenceCC0
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.